Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2010-020337-99
    Sponsor's Protocol Code Number:WA21092
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-03-29
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2010-020337-99
    A.3Full title of the trial
    A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To
    Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To
    Interferon Beta-1a (Rebif) In Patients With Relapsing Multiple Sclerosis.
    Studio randomizzato, in doppio cieco, a doppia simulazione, a gruppi paralleli per valutare l`™efficacia e la sicurezza di ocrelizumab in confronto a interferone Beta-1a (Rebif) in pazienti con sclerosi multipla recidivante.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study of Ocrelizumab in Comparison With Interferon Beta-1a in
    Patients With Relapsing Multiple Sclerosis.
    Studio con Ocrelizumab confrontato con interferone Beta-1a in pazienti con sclerosi multipla recidivante.
    A.3.2Name or abbreviated title of the trial where available
    OPERA I
    OPERA I
    A.4.1Sponsor's protocol code numberWA21092
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01247324
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorROCHE
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann - La Roche Ltd.
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationRoche S.p.A.
    B.5.2Functional name of contact pointS.Scaccabarozzi - Head Clinical Ops
    B.5.3 Address:
    B.5.3.1Street AddressViale G.B. Stucchi 110
    B.5.3.2Town/ cityMonza
    B.5.3.3Post code20900
    B.5.3.4CountryItaly
    B.5.4Telephone number+39 039 247 5070
    B.5.5Fax number+39 039 247 5084
    B.5.6E-mailITALY.INFO_CTA@ROCHE.COM
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOcrelizumab
    D.3.2Product code RO4964913
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOCRELIZUMAB
    D.3.9.1CAS number 637334-45-3
    D.3.9.2Current sponsor codeRO4964913
    D.3.9.3Other descriptive nameNA
    D.3.9.4EV Substance CodeSUB25847
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeanticorpo monoclonale umanizzato
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Rebif
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Serono Europe Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNINTERFERON BETA-1A
    D.3.9.1CAS number 220581-49-7
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameNA
    D.3.9.4EV Substance CodeSUB12440MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number8.8 to 22
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Rebif
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Serono Europe Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNINTERFERON BETA-1A
    D.3.9.1CAS number 220581-49-7
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameNA
    D.3.9.4EV Substance CodeSUB12440MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number22
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Rebif
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Serono Europe Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNINTERFERON BETA-1A
    D.3.9.1CAS number 220581-49-7
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameNA
    D.3.9.4EV Substance CodeSUB12440MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number44
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboConcentrate for solution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    D.8 Placebo: 3
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsing Multiple Sclerosis
    Sclerosi multipla recidivante
    E.1.1.1Medical condition in easily understood language
    Relapsing multiple sclerosis is characterized by relapses followed by periods of full or partial recovery
    La Sclerosi multipla recidivante è caratterizzata da recidive seguite da periodi di recupero completo o parziale
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10063399
    E.1.2Term Relapsing-remitting multiple sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to assess whether the efficacy of
    ocrelizumab 600 mg (given as dual infusions of 300 mg on Days 1 and 15 of
    the first 24-week treatment cycle and as a single infusion of 600 mg on Day 1
    of each 24-week treatment cycle thereafter) intravenously every 24 weeks is
    superior to Rebif as measured by the annualized protocol-defined relapse
    rate by two years (96 weeks) in patients with relapsing multiple sclerosis.
    L’obiettivo primario del presente studio è di valutare se l’efficacia di ocrelizumab 600 mg (somministrato come duplice infusione da 300 mg di ocrelizumab nei Giorni 1 e 15 del primo ciclo di trattamento di 24 settimane, e in seguito sotto forma di infusioni singole da 600 mg nel Giorno 1 di ciascun ciclo di trattamento di 24 settimane) per endovena ogni 24 settimane sia superiore a Rebif come misurato dal tasso di recidiva a due anni (96 settimane) definito dal protocollo annualizzato in pazienti con sclerosi multipla recidivante.
    E.2.2Secondary objectives of the trial
    reflected by the following measures:
    • The time to onset of sustained disability progression for at least 12 weeks during the 96-week comparative treatment period.
    • The time to onset of sustained disability progression for at least 24 weeks during the 96-week comparative treatment period.
    • The proportion of relapse-free patients by 96 weeks.
    • The change in total T2 lesion volume as detected by brain MRI from
    baseline to Week 96.
    • The total number of new, and/or enlarging T2 hyperintense lesions as
    detected by brain MRI at weeks 24, 48 and 96.
    • The change in Multiple Sclerosis Functional Composite Scale (MSFCS)
    score from baseline to Week 96.
    • The change in brain volume as detected by brain MRI from Week 24 to
    Week 96.
    Valutare se l’efficacia di ocrelizumab sia superiore a Rebif, in base alle seguenti misurazioni:
    •il tempo all’insorgenza della progressione della invalidità sostenuta per almeno 12 settimane durante il periodo di trattamento comparativo di 96 settimane.
    •il tempo all’insorgenza della progressione dell’invalidità sostenuta per almeno 24 settimane durante il periodo di trattamento comparativo di 96 settimane.
    •la percentuale di pazienti senza recidiva a 96 settimane.
    •la variazione del volume totale della lesione T2 risultante alla RMI cerebrale dal basale alla Settimana 96.
    •il numero totale di lesioni iperintense T2 nuove e/o in espansione individuate alla RMI cerebrale alle settimane 24, 48 e 96.
    •il cambiamento di punteggio nella scala Multiple Sclerosis Functional Composite Scale (MSFCS) dal basale alla Settimana 96.
    •la variazione del volume cerebrale individuata.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Ability to provide written, informed consent and to be compliant with the schedule of protocol assessments.
    2. Ages 18-55 years at screening, inclusive.
    3. Diagnosis of MS, in accordance with the revised McDonald criteria (2010).
    4. At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the year prior to screening (but not within
    30 days prior to screening).
    5. Neurological stability for ≥ 30 days prior to both screening and baseline.
    6. EDSS, at screening, from 0 to 5.5 inclusive.
    7. Documented MRI of brain with abnormalities consistent with MS prior to screening.
    8. Patients of reproductive potential must use reliable means of contraception
    as described below as a minimum (adherence to local requirements, if more stringent, is required*):
    • Two methods of contraception throughout the trial, including the active treatment phase AND for 48 weeks after the last dose of ocrelizumab,
    or until their B-cells have repleted, whichever is longer. Acceptable
    methods of contraception include one primary (e.g. systemic hormonal
    contraception or tubal ligation of the female partner, vasectomy of the
    male partner) AND one secondary barrier method (e.g. latex condoms,
    spermicide) OR a double barrier method (e.g. latex condom,
    intrauterine device, vaginal ring or pessary plus spermicide [e.g. foam,
    vaginal suppository, gel, cream]).9. For patients of non reproductive potential (adherence to local
    requirements, if more stringent, is required*):
    • Women may be enrolled if postmenopausal (i.e. spontaneous
    amenorrhea for the past year confirmed by an FSH level greater than
    40 mIU/mL) unless the patient is receiving a hormonal therapy for their
    menopause or surgically sterile (i.e. hysterectomy, complete bilateral
    oophorectomy);
    • Men may be enrolled if they are surgically sterile (castration).
    * Based on local Ethics Committees or National Competent Authority feedback
    additional requirements to assure contraception or to confirm menopause may be required (e.g. serum estradiol compatible with post-menopause status,
    longer duration of amenorrhea, higher level of FSH).
    1.Capacità di fornire il consenso scritto informato e di rispettare il programma delle valutazioni da protocollo.
    2.Età 18-55 anni inclusi, allo screening.
    3.Diagnosi di SM, in base ai criteri McDonald rivisti (2010).
    4.Almeno 2 attacchi clinici documentati negli ultimi 2 anni prima dello screening o un attacco clinico nell’anno precedente allo screening (ma non nei 30 giorni precedenti lo screening).
    5.Stabilità neurologica per ≥ 30 giorni prima dello screening e del basale.
    6.EDSS, allo screening, da 0 a 5,5 incluso.
    7.RMI cerebrale documentata con anomalie coerenti con la SM prima dello screening.
    8. I pazienti con potenziale riproduttivo devono usare come minimo i mezzi affidabili di contraccezione descritti di seguito (è richiesta l’adesione ai requisiti locali, se più stringenti*):
    •due metodi di contraccezione nel corso della sperimentazione, compresa la fase di trattamento attivo E per 48 settimane dopo l’ultima dose di ocrelizumab, o fino alla replezione delle cellule B, qualunque sia il periodo più lungo. I metodi accettabili di contraccezione comprendono uno primario (ad es., contraccezione ormonale sistemica o chiusura delle tube della partner di sesso femminile, vasectomia del partner di sesso maschile) E un metodo barriera secondario (ad es., preservativi in lattice, spermicida) OPPURE un metodo a doppia barriera (ad es., preservativo in lattice, spirale, anello vaginale o pessario più spermicida [ad es., schiuma, supposta vaginale, gel, crema]).
    9.Per i pazienti senza potenziale riproduttivo (è richiesta l’adesione ai requisiti locali, se più stringenti*):
    •le donne possono essere arruolate se in postmenopausa (cioè, amenorrea spontanea per l’anno precedente confermata da un livello di FSH superiore a 40 mIU/ml) a meno che la paziente non riceva una terapia ormonale per la menopausa o sia chirurgicamente sterile (cioè, isterectomia, ooforectomia bilaterale completa);
    •gli uomini possono essere arruolati se sono chirurgicamente sterili (castrazione).

    * In base al riscontro dei Comitati etici locali o dell’Autorità nazionale competente possono essere necessari dei requisiti aggiuntivi per assicurare la contraccezione o per confermare la menopausa (ad es., estradiolo sierico compatibile con lo stato post-menopausale, durata maggiore della amenorrea, innalzamento del livello di FSH).
    E.4Principal exclusion criteria
    1. Diagnosis of primary progressive MS.
    2. Disease duration of more than 10 years in patients with an EDSS ≤ 2.0 at
    screening.
    3. Inability to complete an MRI (contraindications for MRI include but are not restricted to claustrophobia, weight ≥ 140 kg, pacemaker, cochlear
    implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent
    implanted within 8 weeks prior to the time of the intended MRI, etc).
    4. Known presence of other neurological disorders which may mimic MS including but not limited to: neuromeylitis optica, Lyme disease, untreated vitamin B12 deficiency, neurosarcoidosis and cerebrovascular disorders.
    Exclusions Related to General Health
    5. Pregnancy or lactation.
    6. Any concomitant disease that may require chronic treatment with systemic
    corticosteroids or immunosuppressants during the course of the study.
    7. History or currently active primary or secondary immunodeficiency.
    8. Lack of peripheral venous access.
    9. History of severe allergic or anaphylactic reactions to humanized or
    murine monoclonal antibodies.
    10. Significant or uncontrolled somatic disease or any other significant disease that may preclude patient from participating in the study.
    11. Congestive heart failure (NYHA III or IV functional severity).
    12. Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds.
    13. Infection requiring hospitalization or treatment with i.v. antibiotics within
    4 weeks prior to baseline visit or oral antibiotics within 2 weeks prior to baseline visit.
    14. History or known presence of recurrent or chronic infection (e.g., hepatitis B or C, HIV, syphilis, tuberculosis).
    15. History of progressive multifocal leukoencephalopathy (PML)
    16. History of malignancy, including solid tumors and hematological
    malignancies, except basal cell carcinoma, in situ squamous cell
    carcinoma of the skin, and in situ carcinoma of the cervix of the uterus that have been previously completely excised with documented, clear margins.
    17. History of alcohol or drug abuse within 24 weeks prior to baseline.
    18. History or laboratory evidence of coagulation disorders. Et al...
    1.Diagnosi di SM primaria progressiva.
    2.Durata della malattia di oltre 10 anni in pazienti con un EDSS ≤ 2,0 allo screening.
    3.Incapacità di completare una RMI (le controindicazioni alla RMI comprendono, tra le altre, claustrofobia, peso ≥ 140 kg, pacemaker, impianti cocleari, presenza di sostanze estranee nell’occhio, clip vascolari intracraniche, chirurgia nelle 6 settimane precedenti all’ingresso nello studio, stent coronarico impiantato nelle 8 settimane precedenti alla data della RMI programmata, ecc.).
    4.Presenza nota di altri disturbi neurologici che possano simulare la SM tra cui: neuromielite ottica, malattia di Lyme, carenza di vitamina B12 non trattata, neurosarcoidosi e disturbi cerebrovascolari.
    Esclusioni correlate alla salute generale
    5.Gravidanza o allattamento.
    6.Qualunque malattia concomitante che può richiedere un trattamento cronico con corticosteroidi sistemici o immunosoppressori nel corso dello studio.
    7.Anamnesi o presenza di immunodeficienza attiva primaria o secondaria.
    8.Mancanza di accesso venoso periferico.
    9.Anamnesi di gravi reazioni allergiche o anafilattiche agli anticorpi monoclonali umanizzati o murini.
    10.Malattia somatica significativa o non controllata o altra malattia significativa che possa precludere al paziente la partecipazione allo studio.
    11.Insufficienza cardiaca congestizia (gravità funzionale NYHA III o IV).
    12.Infezione nota attiva batterica, virale, fungina, micobatterica o di altro tipo, esclusa l’infezione fungina del letto ungueale.
    13.Infezione che richiede il ricovero o il trattamento con antibiotici e.v. nelle 4 settimane precedenti alla visita basale o antibiotici orali nelle 2 settimane prima della visita basale.
    14.Anamnesi o presenza nota di infezione cronica o ricorrente (ad es., epatite B o C, HIV, sifilide, tubercolosi).
    15.Anamnesi di leucoencefalopatia multifocale progressiva (LMP).
    16.Anamnesi di neoplasia maligna, compresi tumori solidi e neoplasie maligne ematologiche, tranne il carcinoma cutaneo basocellulare, in situ carcinoma cutaneo squamocellulare, e carcinoma in situ della cervice uterina completamente escissi in precedenza con margini chiari e documentati.
    17.Anamnesi di abuso di alcool o droghe nelle 24 settimane precedenti al basale.
    18. Anamnesi o evidenza di laboratorio di disturbi della coagulazione. E altri..
    E.5 End points
    E.5.1Primary end point(s)
    - Assessment of clinical and protocol defined relapses
    –Valutazione di recidive cliniche e definite dal protocollo
    E.5.1.1Timepoint(s) of evaluation of this end point
    96 weeks
    96 settimane
    E.5.2Secondary end point(s)
    • The time to onset of sustained disability progression.
    • The proportion of relapse-free patients.
    • The change in brain volume as detected by brain MRI.
    Et al...
    • Valutazione della progressione della invalidità sostenuta.
    • Percentuale di pazienti liberi da recidive.
    • Cambiamenti del volume cerebrale valutati mediante MRI.
    E altri..
    E.5.2.1Timepoint(s) of evaluation of this end point
    Assessments will be made at week 24,48,96
    Le valutazioni saranno effettuate alla settimana 24,48,96
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    double dummy
    double dummy
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA92
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Brazil
    Chile
    Israel
    Mexico
    Morocco
    New Zealand
    Peru
    Russian Federation
    South Africa
    Switzerland
    Tunisia
    Ukraine
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study has been defined as the date at which the last data point from the last patient, which was required for statistical analysis as defined in Data Analysis Plan (DAP), was received.
    La fine dello studio è stata definita quale la data in cui sia stato ricevuto l’ultimo punto dati dall’ultimo paziente, che era stato richiesto per l’analisi statistica per come definito nel Piano di analisi dati (DAP).
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months45
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months45
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 800
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 333
    F.4.2.2In the whole clinical trial 800
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients who complete the comparative phase of treatment period will
    be offered treatment with ocrelizumab during the optional ocrelizumab
    extension phase. Patients previously treated with Rebif will be
    offered open label ocrelizumab treatment.
    Ai pazienti che completeranno la fase comparativa sarà offerta la possibilità di continuare il trattamento con ocrelizumab nella fase di estensione opzionale.I pazienti precedentemente trattati con Rebif potranno essere trattati in aperto con ocrelizumab.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2011-09-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2011-09-19
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2022-12-31
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 01:00:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA